Proceedings of the Texas A&M Medical Student Grand Rounds

Ferritin H’s Role in Iron-related Molecular Pathways Leading to Congestive Heart Failure Predisposition

June 27, 2022 Charles Foster

Charles Foster

Introduction. Congestive heart failure (CHF) is a common cardiopulmonary condition that is characterized by decreased cardiac output, particularly with reduced ejection fraction. CHF is one of the most prevalent causes of respiratory failure in the adult U.S. population.1 Diagnosis of CHF often cannot be made by physical exam alone, as its symptoms are often non-specific and patients with less severe CHF may have no clinical presentation at all.2 Furthermore, current diagnostic modalities are often not specific for CHF. At best, this leads to operator-dependent outcomes in CHF patients. At worst, less severe CHF patients may be left untreated for long periods of time until severity increases.3 This is why it is so crucial to develop ways not only to quickly and accurately diagnose patients with CHF, but also identify patients with existing predisposition to CHF to monitor for early signs of the disease. Methods. The metabolism of iron is well established in playing a key role in the development of cardiomyopathy and CHF.4 Ferritin is a key metabolite in storing excess iron, but its exact mechanism of function in cardiac myocytes remains unknown.5 In this study attempting to explore the role of Ferritin H, a subtype of Ferritin normally present in cardiac myocytes, knockout mice were produced lacking Ferritin H allele expression specifically in cardiomyocytes. This knockout allele was confirmed via PCR analysis of genomic DNA. These knockout mice were then compared to normal mice expressing these alleles. RNA sequencing and collection of oxylipids, amino acids, and cardiac enzymes were performed for analysis.6 Results. Knockout mice lacking Ferritin H exhibited decreased levels of cardiac iron as well as increased oxidative stress. Interestingly, this study also found that supplementing these mice with high doses of iron also caused cardiac dysfunction and myopathy. Molecular analysis of cardiac tissue after supplemental iron dosing revealed evidence of ferroptosis, such as severely decreased levels of glutathione and increased lipid peroxidation. Additionally, analysis found that mice deficient in Ferritin H downregulated the expression of Slc7a11, a potent regulator of ferroptosis in cardiac tissue. Slc7a11 was also shown to increase glutathione levels and prevent cardiac ferroptosis. Therefore, Ferritin H deficiency-mediated downregulation of this gene was a potent originator of cardiomyocyte dysfunction.6 Conclusions. Ferritin H may be a key regulator of cardiomyocyte function in cardiomyopathy and CHF. Patients suspected of predisposition to CHF should have their levels of ferritin evaluated in order to diagnose and/or manage this condition.

  1. Figueroa, M., & Peters, J. Congestive heart failure: Diagnosis, pathophysiology, therapy, and implications for respiratory care. Respiratory Care. 2006; 5(4); 403-412.
  2. Watson, R., Gibbs, C., & Lip, G. ABC of heart failure: Clinical features and complications. British Medical Journal. 2000; 320; 236-239.
  3. Jahmunah, V., Lih Oh, S., Wei, J., et al. Computer-aided diagnosis of congestive heart failure using ECG signals – A review. European Journal of Medical Physics. 2019; 62; 95-104.
  4. Hentze, M.W., Muckenthaler, M.U., Galy, B., & Camaschella, C. Two to tango: regulation of Mammalian iron metabolism. Cell. 2010; 142; 24-38.
  5. Ganz, T. Systemic iron homeostasis. Physiol Rev. 2013; 93; 1721-1741.
  6. Fang, X., Cai, Z., Wang, H., & Han, D., et al. Loss of Cardiac Ferritin H Facilitates Cardiomyopathy via Slc7a11-Mediated Ferroptosis. Circulation Research. 2020; 127; 486-501.

 

 

Cardiology Engineering Medicine
Previous Post

Immune System Modulators as Treatment for Secondary Bacterial Pneumonia Following Influenza A Infection

Next Post

Impact of B-adrenergic Receptors in the Development, Diagnosis and Treatment of Takotsubo Cardiomyopathy

Scientific Editors

Steve A. Maxwell

Executive Editor
Tel: 979-436-0804
smaxwell@medicine.tamhsc.edu

Robin Fuchs-Young

Deputy Editor
Tel: 979-845-5109
fuchs-young@medicine.tamhsc.edu
Administrative Editor

Janis Chmiel

Tel: 979-436-0856
chmiel@medicine.tamhsc.edu
Editorial Office
Tel.: 979-845-2726
Fax: 979-847-9481
chmiel@medicine.tamhsc.edu
Archives
  • July 2026
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • May 2025
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • November 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • August 2022
  • June 2022
  • May 2022
  • August 2021
  • July 2021
  • April 2021
  • October 2020
  • August 2020
  • July 2020
  • August 2019
  • July 2019
  • February 2019
  • July 2018
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • January 2017
Proudly powered by WordPress | Theme: Fmi by Forrss.